Efficacy of ETI Therapy for Cystic Fibrosis N1303K Variant
發布者：Unknown
·發布於：2025-12-13
Discussion regarding the effectiveness of the triple combination therapy Elexacaftor + Tezacaftor + Ivacaftor (ETI) in restoring CFTR function specifically for patients with the N1303K variant of cystic fibrosis.
載入中...